Paper42809697PubMed
CAR-T Cell Therapy: Engineering Remission in Refractory Myeloma.
Sperling AS. Cancer J, 2026.
Cite this record
ConductScience Library. CAR-T Cell Therapy: Engineering Remission in Refractory Myeloma. Papers, record 42809697. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42809697
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- CAR-T Cell Therapy: Engineering Remission in Refractory Myeloma.
- Journal
- Cancer J
- Year
- 2026
- Publication types
- Journal Article, Review, Research Support, N.I.H., Extramural
- Revised in PubMed
- 2026-10-06
Source PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Multiple Myeloma | Major topic |
| Immunotherapy, Adoptive | Major topic |
| Receptors, Chimeric Antigen | Major topic |
| T-Lymphocytes | Major topic |
| Humans | |
| Remission Induction | |
| Treatment Outcome |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA124435 | NCI NIH HHS | United States | P30CA124435 | PubMed | NIH RePORTER |
| R01 DK141535 | NIDDK NIH HHS | United States | R01DK141535 | PubMed | NIH RePORTER |
References72
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 41285709 | TSCM-predominant allogeneic anti-BCMA CAR-T therapy for relapsed/refractory multiple myeloma: preclinical characterization and interim results from a phase 1 trial. | Nat Commun | 2025 | https://conductscience.org/library/papers/41285709 | PubMed |
| 2 | 30102295 | Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. | Nat Biotechnol | 2018 | https://conductscience.org/library/papers/30102295 | PubMed |
| 3 | 33626253 | Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. | N Engl J Med | 2021 | https://conductscience.org/library/papers/33626253 | PubMed |
| 4 | 37486599 | Respiratory infections predominate after day 100 following B-cell maturation antigen-directed CAR T-cell therapy. | Blood Adv | 2023 | https://conductscience.org/library/papers/37486599 | PubMed |
| 5 | 40198886 | Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma. | Blood | 2025 | https://conductscience.org/library/papers/40198886 | PubMed |
| 6 | 15731182 | Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. | Blood | 2005 | https://conductscience.org/library/papers/15731182 | PubMed |
| 7 | 41968163 | Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma. | Blood Cancer J | 2026 | https://conductscience.org/library/papers/41968163 | PubMed |
| 8 | 28954221 | Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18. | Cell Rep | 2017 | https://conductscience.org/library/papers/28954221 | PubMed |
| 9 | 29061640 | Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma. | Clin Cancer Res | 2018 | https://conductscience.org/library/papers/29061640 | PubMed |
| 10 | 41540108 | Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma. | Nat Med | 2026 | https://conductscience.org/library/papers/41540108 | PubMed |
| 11 | 34175021 | Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. | Lancet | 2021 | https://conductscience.org/library/papers/34175021 | PubMed |
| 12 | 38977912 | A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. | Nat Med | 2024 | https://conductscience.org/library/papers/38977912 | PubMed |
| 13 | 37653344 | Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. | Nat Med | 2023 | https://conductscience.org/library/papers/37653344 | PubMed |
| 14 | 41825801 | Characterization of Hypogammaglobulinemia, Infection Incidence, and Mortality in Patients Receiving B-cell Maturation Antigen Chimeric Antigen Receptor (CAR) T-cell Therapy. | Transplant Cell Ther | 2026 | https://conductscience.org/library/papers/41825801 | PubMed |
| 15 | 37525244 | The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma. | J Hematol Oncol | 2023 | https://conductscience.org/library/papers/37525244 | PubMed |
| 16 | 41411617 | Clinical and Cytokine Features of Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome. | Blood Cancer Discov | 2026 | https://conductscience.org/library/papers/41411617 | PubMed |
| 17 | 36906275 | Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome. | Transplant Cell Ther | 2023 | https://conductscience.org/library/papers/36906275 | PubMed |
| 18 | 41519141 | Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial. | Lancet Oncol | 2026 | https://conductscience.org/library/papers/41519141 | PubMed |
| 19 | 33846552 | CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma. | Gene Ther | 2021 | https://conductscience.org/library/papers/33846552 | PubMed |
| 20 | 35468618 | Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma. | Blood Adv | 2023 | https://conductscience.org/library/papers/35468618 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| TNFRSF17 | 608 | PubTator's text mining | https://conductscience.org/library/genes/608 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42809697
GET https://conductscience.org/api/papers/v1/42809697/references?page=2